---
title: "Weekly Recap | Glaukos +8.52%, consensus target above spot"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302951298.md"
description: "Glaukos gained 8.52% this week to close at $178.88, while the S&P 500 slipped 0.47%, leaving the stock roughly 8.99 percentage points ahead of the benchmark. The move was mostly one-way: after opening Monday at $164.71, the stock accelerated on Tuesday, pushed above $178 intraday on Wednesday, then held a 174-180 range into Friday’s close at $178.88. There was no major company-specific catalyst this week; the price ended well above its 20-day moving average."
datetime: "2026-10-24T06:21:08.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302951298.md)
  - [en](https://longbridge.com/en/news/302951298.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302951298.md)
generator: "portal-rs"
---

# Weekly Recap | Glaukos +8.52%, consensus target above spot

## The Week

Glaukos gained 8.52% this week to close at $178.88, while the S&P 500 slipped 0.47%, leaving the stock roughly 8.99 percentage points ahead of the benchmark. The move was mostly one-way: after opening Monday at $164.71, the stock accelerated on Tuesday, pushed above $178 intraday on Wednesday, then held a 174-180 range into Friday’s close at $178.88. There was no major company-specific catalyst this week; the price ended well above its 20-day moving average.

## Analyst Ratings

Coverage totals 14 brokers: 10 rate it buy, 3 rate it overweight, and 1 is neutral. There are no underweight or sell ratings. The consensus recommendation is strong buy, with a consensus target of $199.31, about 11.42% above the latest close. Individual targets range from $172 to $225, so dispersion is not trivial. Within the 142-name medical device sector, Glaukos ranks 24th by broker rating.

## The Week Ahead

Glaukos reports fiscal Q3 2026 results after Wednesday’s close on 28 October, with consensus estimates around -$0.18 EPS and $168m revenue — the key event to watch. On Tuesday, a batch of US macro prints including durable goods orders, new home sales and consumer confidence could also shape overall risk appetite.

*This article is generated by LongbridgeAI from market data, for information only and not investment advice.*

### Related Stocks

- [GKOS.US](https://longbridge.com/en/quote/GKOS.US.md)

## Related News & Research

- [How Investors Are Reacting To Glaukos (GKOS) Strong Trial Results](https://longbridge.com/en/news/301938211.md)
- [Glaukos Chief Development Officer Tomas Navratil disposes of common shares worth USD 245,456.09](https://longbridge.com/en/news/300353448.md)
- [AI fever ignites a boom in thematic ETFs as fund managers hunt for their next big hit](https://longbridge.com/en/news/302963080.md)
- [Glaukos Corporation (GKOS) Posts 3-Year Epioxa Phase 3 Extension Data](https://longbridge.com/en/news/301181175.md)
- [17,860 Shares in Marvell Technology, Inc. $MRVL Bought by Atlatl Advisers LLC](https://longbridge.com/en/news/302957117.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**